DCXR monoclonal antibody (M03), clone 6A6
- Known as:
- DCXR mab (anti-) (M03), clonality 6A6
- Catalog number:
- H00051181-M03
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Abno
- Gene target:
- DCXR monoclonal antibody (M03) clone 6A6
Related genes to: DCXR monoclonal antibody (M03), clone 6A6
- Gene:
- CENPJ NIH gene
- Name:
- centromere protein J
- Previous symbol:
- MCPH6
- Synonyms:
- CPAP, BM032, LAP, LIP1, Sas-4, SASS4, SCKL4
- Chromosome:
- 13q12.12-q12.13
- Locus Type:
- gene with protein product
- Date approved:
- 2002-02-15
- Date modifiied:
- 2018-02-13
- Gene:
- CENPN NIH gene
- Name:
- centromere protein N
- Previous symbol:
- C16orf60
- Synonyms:
- FLJ13607, FLJ22660, BM039
- Chromosome:
- 16q23.2
- Locus Type:
- gene with protein product
- Date approved:
- 2006-02-20
- Date modifiied:
- 2015-08-24
- Gene:
- DCXR NIH gene
- Name:
- dicarbonyl and L-xylulose reductase
- Previous symbol:
- -
- Synonyms:
- KIDCR, DCR, SDR20C1
- Chromosome:
- 17q25.3
- Locus Type:
- gene with protein product
- Date approved:
- 2002-07-25
- Date modifiied:
- 2018-07-10
- Gene:
- DONSON NIH gene
- Name:
- downstream neighbor of SON
- Previous symbol:
- C21orf60
- Synonyms:
- B17, C2TA, DKFZP434M035
- Chromosome:
- 21q22.11
- Locus Type:
- gene with protein product
- Date approved:
- 2000-02-18
- Date modifiied:
- 2017-03-30
- Gene:
- EAPP NIH gene
- Name:
- E2F associated phosphoprotein
- Previous symbol:
- C14orf11
- Synonyms:
- BM036, FLJ20578
- Chromosome:
- 14q13.1
- Locus Type:
- gene with protein product
- Date approved:
- 2002-11-18
- Date modifiied:
- 2016-02-26
Related products to: DCXR monoclonal antibody (M03), clone 6A6
Related articles to: DCXR monoclonal antibody (M03), clone 6A6
- Tuberculosis (TB) remains the leading cause of death among persons with advanced HIV disease (AHD) in high HIV-burden settings. Digital chest X-ray (dCXR) with computer-aided detection (CAD) is a promising tool to overcome human resource constraints and improve TB case detection. This study evaluates the real-world implementation and performance of dCXR/CAD for TB screening within a specialized AHD clinic in Maputo, Mozambique. We conducted a retrospective cohort analysis of 487 new AHD patients at Centro de Referência do Alto Maé (CRAM) from October 2023 to September 2024. Of these, 238 underwent dCXR with CAD interpretation. All patients underwent systematic TB screening according to Ministry of Health (MoH) guidelines. Using the recorded diagnosis of TB (bacteriologically confirmed or clinically diagnosed) as the reference standard, we calculated the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the nationally adopted CAD threshold (≥0.5). Among 238 AHD patients screened with CAD, 116 (49%) were diagnosed with TB. At the ≥0.5 threshold, sensitivity was 50% (58/116; 95% CI: 41-59), specificity 92% (112/122; 95% CI: 85-96), PPV 85% (58/68; 95% CI: 75-92), and NPV 65.9% (112/170; 95% CI: 58-73). TB diagnosis rates increased sharply with CAD score: 30% (43/143) in normal, 52% (15/27) in abnormal non-suggestive, and 85% (58/68) in suggestive cases. Bacteriological confirmation was low across all groups (19-26%), reflecting reliance on clinical diagnosis. Integrating dCXR/CAD into AHD care is feasible and identifies a high TB burden. However, at the adopted threshold of ≥0.5, CAD demonstrated high specificity but low sensitivity (50%) in this population, missing half of all TB cases. These findings suggest that CAD functions better as a confirmatory decision-support tool than a standalone screening test in AHD. Threshold optimization for this specific population warrants prospective evaluation. Implementation challenges including fragmented systems and lack of dedicated human resources must be addressed to realize CAD's full potential in TB programs. - Source: PubMed
Publication date: 2026/07/30
Ruano Camps MariaJose BenditaZindoga PereiraCouto AlenyCumbe CeliaMuvale GilBene RosaCossa Admilson FShapiro Adrienne ELane JeffMudender FlorindoNacarapa Edy - Gestational diabetes mellitus (GDM) poses significant health risks, yet the causal genetic and epigenetic mechanisms linking glycolipid metabolism dysregulation to GDM remain elusive. This study aimed to identify key causal genes and regulatory pathways by integrating multi-omics data with large-scale genetic association studies. - Source: PubMed
Publication date: 2026/05/20
Lin XiaoxiaoZheng JingjingQin NingningLi Yimei - Recent evidence has established a significant link between N4 acetylcytidine (ac4C) mRNA modification, mediated by N Acetyltransferase 10 (NAT10), and bone metabolism. Nonetheless, the precise role and regulatory targets of NAT10, along with its associated ac4C modification in human bone formation, remain inadequately characterized. This study employed bioinformatics analysis of transcriptomic datasets from primary osteoblasts of individuals with high versus low bone mineral density (BMD), alongside a curated set of ac4C-modified genes, to identify key differentially expressed genes (DEGs) regulated by this pathway within an osteogenic context. Overall, eleven key NAT10/ac4C-associated DEGs linked to BMD status were identified: CFD, CTSF, DCXR, FADS1, GOLIM4, IMPA2, MLEC, NCLN, NT5DC2, PTGFRN, and VASP. Notably, FADS1, NT5DC2, and PTGFRN emerged as crucial ac4C-modified genes across three machine learning models. Furthermore, the tri-gene signature (FADS1/NT5DC2/PTGFRN) showed excellent diagnostic performance in distinguishing different BMD statuses. In vitro validation using MC3T3-E1 osteoblastic cells revealed that the knockdown of NAT10 via lentiviral delivery markedly impaired cell proliferation and osteogenic differentiation. This impairment was evidenced by the results of the CCK-8 proliferation assay, alkaline phosphatase staining, and Alizarin Red staining. Additionally, qRT PCR analysis demonstrated a significant downregulation of FADS1 and NT5DC2 expression subsequent to NAT10 knockdown. These findings underscore the role of NAT10-mediated ac4C modification as a pivotal regulator of osteoblast activity and gene expression programs associated with BMD. This research offers novel insights into the regulation of bone metabolism and proposes potential diagnostic markers and therapeutic targets for osteoporosis. - Source: PubMed
Tang YWang QDong WJiang GLei MHu XWu YJiang WHao JHu Z - The World Health Organisation (WHO) recommends digital chest radiography (dCXR) with computer-aided detection (CAD) for tuberculosis (TB) screening of individuals >15 years of age. - Source: PubMed
Publication date: 2026/04/30
Nyangu SarahMulenga HumphreyMendelsohn Simon CPerumal TahliaTameris MicheleMoloantoa TumeloMalherbe Stephanus TNoor FirdowsShenje JustinTredoux NicoletteKany Luabeya Angelique KanyMaruri FernandaPanchia RavindreHlongwane KhuthadzoStanley Kimvan der Heijden Yuri FHadley KateMartinson NeilDheda KeertanLeslie AlFourie BernardWalzl GerhardScriba Thomas JSterling Timothy RHatherill Mark - The World Health Organization recommends community-based tuberculosis active case finding using digital chest radiography with computer-aided detection (dCXR/CAD) and/or molecular diagnostics, but clinical and economic outcomes are unclear. - Source: PubMed
Deleger Julie NKhatami S NazaninJones MichelleJalali Mohammad SPaltiel A DavidWong Emily BFlorance GradyFreedberg Kenneth AWood RobinHorsburgh C RobertReddy Krishna P